

Citi 2016 Global Healthcare Conference

Mikael Dolsten, M.D., Ph.D.
President Pfizer Worldwide R&D
December 8th, 2016



Forward-looking Statements

- This presentation includes forward-looking statements about, among other things, development of Pfizer's products and product candidates, including their potential benefits, expected clinical trial study starts and expected regulatory submissions and approvals that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information.
- Factors that May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the US Securities and Exchange Commission (SEC) and available at www.sec.gov and www.pfizer.com.
- The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.

Strong Track Record of Approvals

Over the last 6 years >30 Phase 3 starts & >15 key approvals (10 NME's)



Robust Pipeline Positioned for Sustainable Productivity

~50% biologics, biosimilars and vaccines



Data as of November 1 2016

2016 A Productive Year for Pfizer R&D

Key Regulatory News Flow

APPROVALS



Adv. BC (EU)
Rec. Adv. BC (US/EU)



ROS+ NSCLC
(US/EU)




QD MR
(US)




Infant
(CN)

SUBMISSIONS



Antibody Drug Conjugates

inotuzumab	Mylotarg
ALL	AML
(US ¹ /EU)	(US/EU ¹)



Immuno Oncology

avelumab
Merkel Cell
(US/EU)




Cardiovascular

ertugliflozin
T2D
(US²)

1 Pending Acceptance; 2 Projected submission

2016 A Productive Year for Pfizer R&D

Key Clinical News Flow



2016 A Productive Year for Pfizer R&D

Leveraging the External Environment

EXTERNAL FOCUS AREAS

SELECT 2016 ACTIVITIES



Strengthen pipelines with highly differentiated, quality assets



Enable Strategic Focus Areas via “Build & Buy” (GTx, I/O)



Access novel targets & breakthrough platforms



Delivering the Next Wave of Innovation

(Potential Clinical Milestones by 2018)



ONCOLOGY

Up to 10 Triplets & Doublets

Cancer Vaccine Triplet
avelumab+41BB+OX40
avelumab+41BB+IDO
avelumab + ADC



RARE DISEASE

3 Gene Therapy Assets

Hemophilia B
DMD
Friedrich's Ataxia



I&I

~10 Ph 2 Selective Kinases

JAK1
JAK3
TYK2/JAK1



CVMET

3 NASH Assets

ACC
KHK
DGAT2



NEURO

Up to 3 AD/PD Assets in Ph 2

Dopamine Modulation
GSM
BACE



VACCINES

Up to 9 Clinical Vaccines

C.Diff
RSV
Pneumo Nexgen

Q&A

